Progress in the development of malaria vaccines
10.11665/j.issn.1000-5048.2024090401
- VernacularTitle:疟疾疫苗的研发进展
- Author:
Ke ZHOU
1
;
Zongxiang CHEN
;
Lanjun LIU
Author Information
1. 成都生物制品研究所有限责任公司, 成都 610023;中国生物技术股份有限公司 新突发传染病新型疫苗研发全国重点实验室，北京 100024;中国药科大学生命科学与技术学院, 南京 211198
- Publication Type:Journal Article 期刊文章
- Keywords:
malaria;
malaria vaccines;
Plasmodium falciparum;
RTS,S/AS01E;
R21/Matrix-M
- From:
Journal of China Pharmaceutical University
2025;56(4):531-538
- CountryChina
- Language:Chinese
-
Abstract:
Malaria is an infectious disease caused by Plasmodium through the bite of female mosquitoes, posing a significant threat to global public health. Since 2000, humans have adopted various measures to prevent and control malaria, but due to the impact of COVID-19, the number of malaria cases has increased rather than decreased, making malaria vaccines one of the focal points for controlling the disease. The Plasmodium that infects humans mainly includes Plasmodium falciparum and Plasmodium vivax. The life cycle of Plasmodium includes the pre-erythrocytic stage, the blood stage, and the mosquito stage. Two vaccines, RTS,S/AS01E, and R21/Matrix-M, which have been pre-qualified by the World Health Organization to target the pre-erythrocytic proteins of Plasmodium falciparum. The clinical trial data show reduction in malaria mortality rates among children, and mass vaccination is currently underway in Africa. However, no malaria vaccines targeting other stages or antigens have yet entered phase III clinical trials. This article describes the hazards and prevention of malaria, summarizes malaria vaccines designed in recent years for the three stages of the Plasmodium life cycle: the pre-erythrocytic stage, the blood stage, and the mosquito stage, and demonstrates the challenges and ideas in the field of malaria vaccine research and development, aiming to provide some reference for the development of novel malaria vaccines.
